血清血管生成素-1、IL-17、骨桥蛋白和CXCL-9升高作为新诊断PMR血管炎症标志物
这项多中心前瞻性纵向研究纳入53例PMR、13例PMR合并亚临床GCA及59例GCA患者,检测血清生物标志物并行血管超声。GCA血清血管生成素-1、血管生成素-2、CXCL-9、骨桥蛋白、IL-6和IL-17显著高于PMR;PMR合并亚临床GCA者基线血管生成素-1、IL-17、骨桥蛋白和CXCL-9显著高于单纯PMR。ROC分析显示上述标志物对识别PMR中血管炎症有一定诊断价值。
要点
- PMR合并亚临床GCA者基线血管生成素-1、IL-17、骨桥蛋白和CXCL-9显著高于单纯PMR。
- GCA血清血管生成素-1、血管生成素-2、CXCL-9、骨桥蛋白、IL-6和IL-17显著高于PMR。
- 血管生成素-1、IL-17、骨桥蛋白和CXCL-9的AUC分别为0.801、0.892、0.814和0.892。
核心结论
- PMR合并亚临床GCA具有更接近GCA而非PMR的生物标志物特征。
- 基线血管生成素-1、IL-17、骨桥蛋白和CXCL-9可能有助于识别PMR中伴血管炎症的患者。
- 这些标志物可能作为筛查工具识别需要进一步检查的PMR患者。
研究设计与样本
- 多中心前瞻性纵向研究,在都柏林Tallaght大学医院和St James医院连续招募新患者。
- 采用BioTechne ELISA试剂盒按制造商方案检测血清生物标志物。
- 患者接受双侧颞动脉和腋动脉标准化血管超声以识别血管炎症。
- 样本来自53例PMR、13例PMR合并亚临床GCA和59例GCA患者。
主要发现
- GCA血清血管生成素-1(P < 0.001)、血管生成素-2(P < 0.001)、CXCL-9(P < 0.001)、骨桥蛋白(P < 0.001)、IL-6(P = 0.02)和IL-17(P < 0.001)显著高于PMR。
- PMR合并亚临床GCA者基线血管生成素-1、IL-17、骨桥蛋白(P < 0.001)和CXCL-9(P = 0.004)均显著高于单纯PMR。
- PMR合并亚临床GCA者与单纯PMR相比,IL-23、血管生成素-2或IL-6无显著差异。
关键数值与推荐
- ROC分析:血管生成素-1的AUC为0.801(敏感性84.6%,特异性70%)。
- ROC分析:IL-17的AUC为0.892(敏感性84.6%,特异性79.2%)。
- ROC分析:骨桥蛋白的AUC为0.814(敏感性84.5%,特异性79.2%)。
- ROC分析:CXCL-9的AUC为0.892(敏感性92.3%,特异性62.3%)。
临床怎么用
- 基线血管生成素-1、IL-17、骨桥蛋白和CXCL-9可能有助于识别PMR中伴血管炎症的患者。
- 这些标志物可能作为筛查工具识别需要进一步检查的PMR患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: GCA and PMR are commonly overlapping diseases. Biomarkers for detecting vascular inflammation in PMR patients are lacking. We aimed to determine the diagnostic value of serum levels of angiopoietin-1, angiopoietin-2, interleukin-6, interleukin-17A, interleukin-23, CXCL-9 and osteopontin (OPN) in identifying vascular inflammation in PMR. METHODS: This was a multicentre prospective longitudinal study at Tallaght University Hospital (TUH) and St James Hospital (SJH), Dublin recruiting consecutive new patients. Serum levels of biomarkers were measured using the BioTechne ELISA assay kits following manufacturer protocols. Patients had standardized vascular ultrasound (US) of bilateral temporal and axillary arteries to identify vascular inflammation. RESULTS: Samples were collected from 53 PMR, 13 subclinical GCA in PMR (sGCA) and 59 GCA patients. GCA serum was significantly different from PMR; with higher levels of angiopoietin-1 (P < 0.001), angiopoietin-2 (P < 0.001), CXCL-9 (P < 0.001), osteopontin (P < 0.001), IL-6 (P = 0.02) and IL-17 (P < 0.001). Angiopoietin-1, IL-17, osteopontin (P < 0.001) and CXCL-9 (P = 0.004) were all significantly elevated in sGCA in PMR compared with pure PMR at baseline. IL-23, angiopoietin-2 or IL-6 was not significantly different in sGCA in PMR compared with pure PMR. ROC analysis produced AUC of 0.801 for angiopoietin-1 (sensitivity 84.6; specificity 70%), 0.892 for IL-17 (sensitivity 84.6%; specificity 79.2), 0.814 for osteopontin (sensitivity 84.5%; specificity 79.2%) and 0.892 for CXCL-9 (sensitivity 92.3%; specificity 62.3%). CONCLUSION: sGCA in PMR has a biomarker signature that more closely resembles GCA than PMR. Baseline levels of angiopoietin-1, IL-17, osteopontin and CXCL-9 may help identify PMR patients with vascular inflammation. These may be a useful screening tool to identify PMR patients that would benefit from further work-up.
引用
- Cowley S, Harkins P, Butler TJ, et al. Elevated levels of serum angiopoietin-1, IL-17, osteopontin and CXCL-9 as markers of vascular inflammation in newly diagnosed PMR. Rheumatology (Oxford). 2026. PMID: 41224713. doi:10.1093/rheumatology/keaf603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。